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Abstract
Both folic acid (FA)- and methoxypoly(ethylene glycol) (mPEG)-conjugated chitosan nanoparticles (NPs) had been
designed for targeted and prolong anticancer drug delivery system. The chitosan NPs were prepared with
combination of ionic gelation and chemical cross-linking method, followed by conjugation with both FA and
mPEG, respectively. FA-mPEG-NPs were compared with either NPs or mPEG-/FA-NPs in terms of their size, targeting
cellular efficiency and tumor tissue distribution. The specificity of the mPEG-FA-NPs targeting cancerous cells was
demonstrated by comparative intracellular uptake of NPs and mPEG-/FA-NPs by human adenocarcinoma HeLa
cells. Mitomycin C (MMC), as a model drug, was loaded to the mPEG-FA-NPs. Results show that the chitosan NPs
presented a narrow-size distribution with an average diameter about 200 nm regardless of the type of functional
group. In addition, MMC was easily loaded to the mPEG-FA-NPs with drug-loading content of 9.1%, and the drug
releases were biphasic with an initial burst release, followed by a subsequent slower release. Laser confocal
scanning imaging proved that both mPEG-FA-NPs and FA-NPs could greatly enhance uptake by HeLa cells. In vivo
animal experiments, using a nude mice xenograft model, demonstrated that an increased amount of mPEG-FA-NPs
or FA-NPs were accumulated in the tumor tissue relative to the mPEG-NPs or NPs alone. These results suggest that
both FA- and mPEG-conjugated chitosan NPs are potentially prolonged drug delivery system for tumor cell-
selective targeting treatments.
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Introduction
There is a wealth of literature related to the develop-
ment of drug delivery carriers for cancer and other dis-
eases. Various drug delivery carriers such as NPs,
liposomes, and micelles display significantly improved
therapeutic efficacy against different tumors. The nano-
sized particles can circulate in the bloodstream for
longer time and offer unique possibilities to overcome
cellular barriers, thus reaching tumor sites more effec-
tively. It has become apparent that, when administered
systemically, the biocompatible NPs preferentially accu-
mulate in solid tumors by the enhanced permeability
and retention (EPR) effect [1,2], attributed to leaky
tumor vessels and lack of the effective lymphatic drai-
nage system. Among the nanosized particles previously
reported, the chitosan NPs [3,4] had drawn increasing
attention as a drug carrier because of its advantages for
biomedical applications such as biocompatibility, biode-
gradability, and biological activities [5-7]. Besides, the
reactive amino groups in the backbone of chitosan make
it possible to chemically conjugate various biological
molecules such as different ligands and antibodies,
which may improve targeting efficiency of the drug to
the site of action [8,9].
Berthold et al. [10] initially prepared chitosan particles
using sodium sulfate as the precipitation agent. Tian
and Groves [11] improved this technique and obtained
600-800-nm chitosan NPs. Ohya et al. [12] used glutar-
aldehyde as a cross-linking agent to cross-link the free
amino groups of chitosan, then emulsified using W/O
* Correspondence: Xly885@163.com; yyfeng.dor1969@163.com
2First Hospital, Xiamen University, Xiamen, 361003, China
3Southeast Hospital, Xiamen University, Zhangzhou, 363000, China
Full list of author information is available at the end of the article
Hou et al. Nanoscale Research Letters 2011, 6:563
http://www.nanoscalereslett.com/content/6/1/563
© 2011 Hou et al; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.emulsifier, producing 5-fluorouracil chitosan particles
(average particle size, 0.8 ± 0.1 μm). Bodmeier et al. [13]
first applied the ionic cross-linking method to prepare
chitosan NPs. Tokumitsu et al. [14] reported that it was
easy to incorporate drugs in chitosan solution by adding
an emulsifier and agitating at high speed to produce 426
± 28-nm chitosan NPs. Chitosan NPs have been pre-
pared either by a method of emulsion cross-linking with
dialdehydes or by a method of ionic gelation with multi-
valent anions such as tripolyphosphate. Both of the
methods have their disadvantages. The former method
needs a large amount of organic solvent (consisting of
light liquid paraffin and heavy liquid paraffin) to serve
as continuous oil phase [15], and the latter have poor
mechanical strength because of weak ionic bond formed
through an electrostatic attraction between chitosan and
sodium triphosphate (STPP) [16]. In this study, an ionic
gelation combined with chemical cross-linking method
was used to prepare chitosan NPs in order to overcome
their disadvantages. However, chitosan NPs used as a
drug delivery system must be present in the circulation
for enough time to reach to its intended target tissue.
Plasma proteins can bind circulating NPs and remove
them from the circulation within seconds to minutes
through the reticuloendothelial system (RES). Imparting
a stealth shielding on the surface of these drug delivery
systems prevents plasma proteins from recognizing
these particles and increasing the systemic circulation
time from minutes to hours or even days [17]. Among
the several strategies to impart particles with stealth
shielding, including surface modification with polysac-
charides, poly(acrylamide), and poly(vinyl alcohol), sur-
face modification with PEG proved to be most effective,
fueling its widespread use [17-19]. PEG modification is
often referred to as PEGylation, and it can prolong
exposure of tumor cells to antitumor drug, EPR effect
[20], and subsequently increase the therapeutic effect of
antitumor drug. PEG offers the advantage that it is non-
toxic and non-immunogenic, leading to approved by the
FDA for internal use in humans and inclusion in the list
of inactive ingredients for oral and parenteral
applications.
While it has been demonstrated that PEGylation of
NPs causes a greater accumulation of drug at the tumor
site by passive targeting, active targeting of the NPs can
aid in selection of the target cell type within the tumor
site and internalization of the NPs to a greater extent
inside the target cells. A wide variety of tumor targeting
ligands exist all coupled to nanocarriers. Folic acid (FA)
targeting is an interesting approach for cancer therapy
[21,22] because it offers several advantages over the use
of monoclonal antibodies. More importantly, elevated
levels of folate receptors are expressed on epithelial
tumors of various organs such as colon, lung, prostate,
ovaries, mammary glands, and brain [23,24]. FA is
known to be non-immunogenic, and FA-conjugated
drugs or NPs are rapidly internalized via receptor-
mediated endocytosis. Furthermore, the use of FA as a
targeting moiety is believed to bypass cancer cell multi-
drug efflux pumps [25]. Nevertheless, few literatures
reported that both FA and mPEG were loaded onto one
kind of chitosan NPs simultaneously.
In this paper, we aim at conjugating both FA and
mPEG to the surface of chitosan NPs in order to reach
their target, prolong blood circulation, and reduce phago-
cytosis. Either FA- or mPEG-modified chitosan NPs (FA-
NPs or mPEG-NPs) were also prepared for comparison.
We chose mitomycin C (MMC) as model drugs to pre-
pare drug-loaded chitosan NPs (MMC-mPEG-FA-NPs)
through a covalent coupling. The preparation of NPs and
the modification of NPs are illustrated in Figure 1.
Experimental
Materials
Chitosan with molecular weight 70,000 (95% degree of
deacetylation) was obtained from Zhejiang Aoxing
(China). Twenty-five percent glutaraldehyde solution,
sodium borohydride, 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride (EDC), and STPP were
acquired from Sinoparm Chemical Reagent. FA was pur-
chased from BBI and mitomycin C was purchased from
Zhejiang Hisun (China). The 2,000-Da succinimidyl ester
of methoxypolyethylene glycol propionic acid (SPA-
mPEG) was purchased from Jiaxing Biomatrik (China).
Preparation of chitosan NPs
One hundred twenty-five-milligram chitosan was dis-
solved in 100 ml of 1.2% acetic acid and then adjusted
the pH to the designated value (pH 5.0) with sodium
hydroxide solution (1 M); 16.7 ml of STPP solution (2.5
mg/ml) was slowly added to the chitosan solution under
intensive stirring.; then 10 ml of aqueous glutaraldehyde
(25%, vol/vol) was added to the resultant mixture, fol-
lowed by stirring for 12 h at 37°C to form chemical
cross-linking NPs, which were isolated by centrifugation
at 12,000 rpm for 30 min; and the deposits (NPs) were
then resuspended in water, followed by the addition of
excessive NaBH4 to reduce the C=N bond of NPs. The
NPs were isolated by centrifugation again, then the
supernatant was decanted, and the NPs were dispersed
in 1 M HCl for 12 h and then dialyzed against the dis-
tilled water until the pH near 7.0 in order to remove the
excess NaBH4, STPP, and glutaraldehyde.
Preparations and characterizations of FA-NPs, mPEG-NPs,
and mPEG-FA-NPs
Two milligrams of FA and 4 ml of NPs suspension (5
mg/ml, distilled water used as solvent) were co-mixed in
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room temperature under dark condition for 1 h, and a
yellow FA-NPs suspension was obtained. The FA-NPs
were collected by centrifugation at 12,000 rpm for 30
min, and the deposit was washed with distilled water
and centrifuged again to remove excess FA.
Twenty milligrams of mPEG-SPA and 2 ml of NPs or
FA-NP suspensions (10 mg/ml, solvent was distilled
water ) were co-mixed and stirred at room temperature
under dark condition for 4 h, and then mPEG-NP or
mPEG-FA-NP suspensions were obtained. Both mPEG-
NP and mPEG-FA-NP suspensions were dialyzed against
distilled water to remove the free mPEG-SPA. Fourier
transform infrared spectroscopy (FTIR) spectra of differ-
ent kinds of NPs as well as FA and mPEG-SPA were
recorded with KBr pellets on a Nicolet AVATR 360
spectrometer (Nicolet Company) at room temperature,
and the spectrums were calculated from 4,000 to 750
cm
-1 at 4 cm
-1 spectral resolution. The average size, the
size distribution, and the zeta-potential of all NPs were
measured using Zetasizer Nano ZS (Malvern Instru-
ments). Prior to analysis, 10 ml of distilled water was
added to a 20-ml vial containing about 10 mg of each
kind of samples.
Preparation of rhodamine B-labeled NPs
Five milligrams of rhodamine B isothiocyanate was dis-
solved in 1 ml of DMSO. Two hundred microliters of
this rhodamine B solution was added to 1 ml of 10 mg/
ml different kinds of modified NPs (NPs, FA-NPs,
mPEG-NPs, and mPEG-FA-NPs), respectively, and then
1m lo f2Mp H9 . 0N a 2CO3/NaHCO3 buffer was added
to the mixtures, which was kept for 12 h at 4°C under
dark condition, and the mixture was dialyzed against dis-
tilled water to remove the free rhodamine B (Figure 2c).
Preparation of MMC-mPEG-FA-NPs
Twenty milligrams of MMC and 10 mg of succinic
anhydride (molar ratio of succinate/MMC = 2:3) are co-
dissolved in 1 ml of pyridine and followed by gentle
Figure 1 Schematic illustration of the preparation of NPs and the modification of NPs. GA, glutaraldehyde; EDC, 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride; STPP, sodium triphosphate.
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dine was removed by a Rotavapor and the residue (suc-
cinate-modified MMC) was dissolved in 2 ml of pH 5.0
PBS. Both 0.5 ml of the succinate-modified MMC solu-
tion and 25 mg of EDC were added to 2 ml of mPEG-
FA-NP suspension (8 mg/ml), stirred at room tempera-
ture for 1 h, and finally, MMC-mPEG-FA-NPs were col-
lected by centrifugation at 12,000 rpm for 30 min. The
deposit (MMC-mPEG-FA-NPs) was washed with a dis-
tilled water to get rid of excess EDC and succinate-mod-
ified MMC. Then the suspensions were centrifuged
again. Lyophilization of the deposit was performed to
obtain dry MMC-mPEG-FA-NPs.
The loading content and the loading efficiency of
MMC were calculated using the equations listed below.
Loading content (% ) =
Weight of drug in the nanoparticles
Weight of nanoparticles
× 100
Loading efﬁciency (% ) =
Weight of drug in the nanoparticles
Weight of the feeding drug
× 100
In vitro drug release study
The drug releases were carried out in 1/15 M pH 6.3, pH
7.4, and pH 8.3 at 37°C by a dialysis method, respectively.
MMC-mPEG-FA-NPs corresponding to 1.7 mg MMC
were suspended in 2.5 ml of PBS, and the suspensions
were put into a dialysis bag with 3,500 molecular weight
cutoff and then the dialysis bag was immersed into 100
ml phosphate buffer, followed by gentle agitation. Peri-
odically, 2 ml of the release medium was withdrawn, and
subsequently, the same volume of fresh PBS was added
into the release medium and the samples were analyzed
by a UV spectrophotometer at 360 nm.
In vitro cellular uptake of different kinds of NPs
Human cervical carcinoma (HeLa) cell lines were pro-
vided by the Shanghai Institutes for Biological Sciences,
and the cells were grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum at
37°C and 5% CO2. Nearly confluent cells in 50-ml tissue
culture flask were washed twice with Hanks’ balanced
salt solutions (HBSS) to remove unattached cells and
medium. Then the cells were trypsinized by 0.1% trypsin
solution and centrifuged at 1,000 rpm for 3 min. The
cell pellet was resuspended in fresh media. Cells (2 ml,
5×1 0
7/L) were plated on 14-mm glass coverslips and
allowed to adhere for 12 h. Subsequently, 200 μl( 1m g /
ml) of rhodamine B-labeled different kinds of NPs
(including NPs, FA-NPs, mPEG-NPs, and mPEG-FA-
Figure 2 The reactions involved in this paper.( a) The modification of FA. (b) The modification of mPEG. (c) Labeled with rhodamine B. (d)
MMC loaded to the NPs.
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bated for further 24 h. After incubation, the NPs were
removed and the wells were washed with ice-cold PBS.
The cells were then harvested by trypsinization and cen-
trifuged at 1,000 rpm for 5 min at 4°C. Finally, the cells
were resuspended in 500 μlo fP B Sa n ds t o r e do ni c e
until analysis. The fluorescence intensity was measured
using confocal laser scanning microscopy.
In vivo optical imaging of different kinds of modified NPs
in animals
Animal procedures were in agreement with the guide-
lines of the Institutional Animal Care and Use Commit-
tee. Mouse hepatoma-22 cells were implanted
subcutaneously into the right hind leg of 4-week-old
male nude mice. Biodistributions and imaging studies
were performed when tumors reached 0.2-0.5 cm in
average diameter. Fluorescence of different modified
N P si nn u d em i c ew a so b t a i n e du s i n gt h eM a e s t r oE X
(CRI) in vivo optical imaging system.
Cell viability assays
A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay was performed to determine cell
viability. HeLa cells were chosen for the cell culture
experiments. HeLa cells (4 × 10
4) were seeded into each
well of a 96-well cell culture plate. After 24 h culture at
37°C and 5% CO2 atmosphere, the cells were exposed to
each sample of MMC-mPEG-FA-NP suspension and
free MMC solution at a concentration of 12, 18, and 24
μM for 24 h. In addition, untreated cells incubated in
HBSS and cell treated with drug-free mPEG-FA-NPs
were used as a negative control to which the viabilities
of drug-treated cells were compared.
Results and discussion
The preparation and characteristics of differential kinds of
NPs
Figure 2 shows the process of the preparation and modifi-
cation of NPs, and the scanning electron microscope
image of both blank NPs and mPEG-FA-NPs is shown in
Figure 3. Both NPs were essentially spherical in shape, but
less cases of the NPs were mono-dispersed particles. It is
common that more NPs were in the form of aggregation
with each other. Table 1 shows the particles size, size dis-
tribution, and zeta-potential of the different kinds of NPs.
Both particle size and zeta-potential were the average of
triplicate measurements for a single sample. As shown,
regardless of all kinds of terminal groups, the chitosan
NPs presented a narrow size distribution with an average
diameter about 200 nm. The PEGylation reduced the zeta-
potential values, confirming the presence of PEG chains
shielding the positive charges present at the NP surface. In
addition, all modified terminal groups had little influence
on particles size, suggesting that the size of NPs was con-
sidered to be dominated by the backbone of chitosan,
which was related with the molecule weight of chitosan.
Nevertheless, detailed influence factors affecting the NP
size need to be further approved.
Figure 4 presents the FTIR spectroscopy of mPEG-
SPA, blank NPs, mPEG-NPs, and mPEG-FA-NPs. Char-
acteristic peaks of mPEG-SPA unite are shown in peaks
2,888 and 1,740 cm
-1. In sample mPEG-FA-NPs, mPEG-
Figure 3 SME images. SME image of blank NPs (A) and mPEG-FA-
NPs (B).
Table 1 The average size and the zeta-potential of
different kinds of NPs
Sample name Z-average diameter Zeta-potential
Mean ± SD (nm) Mean ± SD (mV)
NPs 202.0 ± 1.4 38.5 ± 0.5
FA-NPs 198.2 ± 1.1 33.1 ± 0.7
mPEG-NPs 209.8 ± 0.8 26.6 ± 0.8
mPEG-FA-NPs 210.4 ± 3.4 28.1 ± 0.4
All of the dates were obtained using the Zetasizer Nano ZS (Malvern
Instruments)
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Page 5 of 11SPA peak of 1,740 cm
-1 disappeared, but the other char-
acteristic peak of 2,888 cm
-1 was observed, indicating
that mPEG group was conjugated to chitosan NPs.
Typical signals of FA appear at peaks of 1,695 cm
-1,
which also disappeared in sample of mPEG-FA-NPs,
together with results of the yellow color of mPEG-FA-
NPs obtained, and it was indicated that FA group was
also conjugated to chitosan NPs.
The drug loading efficiency and loading content in NPs
MMC was used as a chemotherapeutic agent by virtue
of its antitumor activity. But MMC shows no func-
tional group that could be directly reacted with the
NPs. In this study, succinate was chosen as a linker.
MMC was reacted with succinic anhydride in advance,
and then the succinate-modified MMC (suc-MMC)
reacted with mPEG-FA-NPs in the presence of EDC.
The loading efficiency and loading content of MMC
on mPEG-FA-NPs were 29.2 ± 3.2% and 9.1 ± 1.6%,
respectively. The drug-loading content was influenced
by the functional group because part of the amino
group on the backbone of NPs were consumed by the
modifications of mPEG or/and FA and MMC was
coupled to NPs through the amino group on the sur-
face of NPs, so the mPEG-FA-NPs had a low drug
loading efficiency.
Figure 4 The FTIR spectroscopy of FA, mPEG-SPA, blank NPs, mPEG-NPs, and mPEG-FA-NPs.
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Figure 5 shows the drug release behaviors of the MMC-
m P E G - F A - N P si np H6 . 3 ,p H7 . 4 ,a n dp H8 . 3P B Sa t
37°C, respectively. As the result showed, the drug
releases were somewhat biphasic with an initial burst
release, followed by a subsequent slower release. The
initial burst release should be owed to the presence of
free drug absorbed on the surface of NPs, while the sus-
tained drug release was attributed to the cleavage of the
chemical bond between MMC and suc-chitosan parti-
cles. In addition, longer PEG chain may decrease the
cleavage rate of MMC from the chitosan nanoparticles.
It is also worth noting that the release profiles show a
pH dependence. The higher the medium pH, the faster
the release of MMC from the NPs. This is because
higher pH weakens the drug-suc-chitosan interaction by
deprotonation of the carboxyls in succinate. Since MMC
was one of the typical time-dependent drugs, the MMC-
mPEG-FA-NPs show an adequate prolonged drug
release, suggesting that they have potential as a long-
lasting and effective MMC delivery system.
In vitro cellular uptake of different kinds of NPs
To visualize the effect of FA-mediated endocytosis of
different kinds of modified NPs, the distribution of rho-
damine B-labeled NPs on HeLa cells was observed by
confocal laser scanning microscopy (Figure 6). By 24-h
incubation time, both FA-NPs and mPEG-FA-NPs show
high intracellular rhodamine B concentration, which was
visualized by red intensity of rhodamine B. Nevertheless,
in case of mPEG-NPs, rhodamine B was significantly
localized probably in the outside of the cells instead of a
distribution in the endosomes, indicating that the
mPEG-NPs tended to reduce the cell uptakes. In con-
trast, for blank NPs (Figure 6a), only low red intensity
appeared in the peripheral region of the cells due to
slow diffusion process into the cells for 24-h incubation
period. NPs are generally internalized into cells via fluid
phase endocytosis [26], phagocytosis [27], or receptor-
mediated endocytosis [28]. Physicochemical characteris-
tics such as particle size and surface properties played
key roles in the cellular of NPs [29]. NP uptake could
be considered as an adhesion process followed by an
internalization process [30]. However, surface modifica-
tion of NPs with PEG in our result seems to oppose
uptake by the HeLa cells, which is mainly due to the
formation of a dense, hydrophilic cloud of long flexible
chains on the surface of the NPs that reduces the hydro-
phobic interactions with the membrane of tumor cells.
The chemically anchored PEG chains can undergo spa-
tial conformations, thus preventing the internalization of
NPs by the cells. Yet, FA-mPEG-NPs still presented
obvious cellular uptake similar to FA-NPs, indicating
that PEG modification had minor influence on the FA
receptor-mediated intracellular delivery process.
In vivo imaging of different kinds of NPs in animals
Same as the cell tests, all kinds of the NPs were labeled
by rhodamine B in advance; 0.2 ml suspension of blank
NPs at the concentration of 5 mg/ml was administrated
by injection into the tail vein of nude mice, and the
resulting images were shown in Figure 7A. Immediately
after tail vein injection, fluorescence emitted from the
nude was easily visualized in the superficial vasculature
of the whole body. Subsequently, as blood circulated,
more NPs were deposited in liver.
Considering that biodistribution in tumor-bearing ani-
mals may be different from that in normal animals due
to some physiological changes brought about by tumor
development, hepatoma-22-bearing nudes were
employed in the biodistribution investigation. To inves-
tigate the distribution of four kinds of NPs in various
organs, the nudes were sacrificed immediately after 12 h
of intravenous injection, and the amount of NPs within
t h eo r g a n sw e r ea n a l y z e db yi nv i v oi m a g i n gs y s t e mt o
visualize the disposition of the NPs. As shown in Figure
7B, the mPEG-NPs exhibited weakest fluorescence in
tumors among the four kinds of NPs, indicating that the
mPEG-NPs did not have the ability to specifically bind
to tumor. The result also shows that both FA-NPs and
mPEG-FA-NPs (Figure 7B b, d) were more fluorescent
than NPs without FA-modified (Figure 7B, a, c), sug-
gesting that the accumulations of both FA-NPs and
m P E G - F A - N P si nt u m o r sw e r em e d i a t e db yf o l a t e
receptor. This is in agreement with the results of in
vitro cellular uptake. In addition, the fluorescence inten-
sity of mPEG-modified NPs (concluding mPEG-NPs and
mPEG-FA-NPs) in liver and spleen was significantly
lower than that of other kinds of NPs. This observation
Figure 5 Drug release from MMC-mPEG-FA-NPs in 1/15 M
phosphate buffer at 37°C. pH = 6.3 (square), pH = 7.4 (circle), pH
= 8.3 (triangle).
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with a variety of PEGylated drug delivery systems
[31-34]. As reported, mPEGylation can dramatically
reduce serum protein adsorption, prevent the attraction
of opsonins, and avoid uptake by RES, so as to prolong
their residence time in blood and further accumulate in
tumor owing to EPR effect.
Cell viability assays of MMC loaded NPs
The cytotoxic activities of free MMC, drug-free mPEG-
FA-NPs, and MMC-mPEG-FA-NPs were evaluated by
MTT assay at different concentrations of MMC using the
HeLa cell line. Figure 8 shows that the reduction in cell
viability by free MMC and MMC-mPEG-FA-NPs was
not significantly different, and cell viability was totally
suppressed in a concentration-dependent manner after
24 h of incubation. No cytotoxic activity was observed
for the drug-free mPEG-FA-NPs, indicating that mPEG-
FA-NPs did not affect the mechanism of action of MMC.
It should be emphasized that in the case of MMC-
mPEG-FA-NPs, the cytotoxicity observed was only
attributed to MMC (dug-free NPs were non-cytotoxic).
During the first 24 h of incubation, the significant
amount of free MMC released from the nanoparticles
could be available to mediate some cytotoxicity. Never-
theless, the cytotoxic effect may be a result of the pre-
s e n c eo ff r e eM M Co rM M C - l o a d e dN P so ra
combination of both.
Figure 6 Confocal images. Confocal images of HeLa cells after incubated 24 h with different kinds of modified NPs at the same concentration
0.1 mg/ml; the nuclei were stained by DAPI (blue), and all of the NPs are labeled by rhodamine B (red). (a) Incubated with pure NPs; (b)
incubated with FA-NPs; (c) incubated with mPEG-NPs; (d) incubated with mPEG-FA-NPs.
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Page 8 of 11Figure 7 Fluorescence images.( A) Real-time in vivo fluorescence imaging of intravenously inject with 1 mg NPs without modified at different
time points, after injection. (B) Representative fluorescence images of dissected organs of nude mice-bearing hepatoma-22 sacrificed 12 h after
intravenous injection of different NPs. (a) NPs, (b) FA-NPs, (c) mPEG-NPs, (d) mPEG-FA-NPs. 1, tumor; 2, lung; 3, heart; 4, spleen; 5, kidney; 6, liver.
All images were acquired under the same conditions (1 mg NPs per mouse).
Figure 8 In vitro viability of HeLa cells. In vitro viability of HeLa cells treated with a different concentration of free MMC and MMC loaded
mPEG-FA-NPs after 24 h. Indicated values were mean ± SD (n = 3). **P < 0.01.
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This novel method to prepare the chitosan NPs was
advantageous in terms of a narrow and controllable size
distribution. The mPEG-FA-NPs were shown to be
taken up by target cells at higher levels than mPEG-NPs
and NPs alone. This confirmed that FA retained its tar-
geting ability after conjugation onto NPs and that
mPEG-FA-NPs can effectively target the cells overex-
pressing FA receptors. By combining the biocompatibil-
ity and dispersivity of PEG with the specific cell
targeting capability of FA, we take advantage of a syner-
gistic effect that results in greatly increased nanoparticle
uptake by tumor cells and prolonged blood circulatory
time due to reducing the clearance of NPs by the reticu-
loendothelial system. These results suggest that the
synthesized mPEG-FA-NPs can be used as a potentially
prolonged anticancer drug car r i e rf o rt u m o rc e l l - s e l e c -
tive targeting treatments.
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